DDAVP/Desmopressin 4 micrograms/ml Solution for Injection
*Company:
Ferring Ireland LimitedStatus:
UpdatedLegal Category:
Product subject to restricted prescription (C)Active Ingredient(s):
*Additional information is available within the SPC or upon request to the company
Updated on 20 May 2026
File name
DDAVP_Desmopressin 4 micrograms-ml Solution for Injection-SPC-13.05.2026-cl.pdf
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 20 May 2026
File name
DDAVP_Desmopressin 4 micrograms-ml Solution for Injection-PIL-13.05.2026-cl.pdf
Reasons for updating
- New PIL for new product
Updated on 26 May 2015
Reasons for updating
- New SPC for new product
Legal category:Product subject to restricted prescription (C)
Updated on 26 May 2015
Reasons for updating
- Change to product name
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Change to product name: update document title to align with SPC name
Section 4.8: Update to include new HPRA contact information
Section 4.8: Update to include new HPRA contact information
Updated on 26 May 2015
Reasons for updating
- Change to product name
- Change to Section 4.8 – Undesirable effects - how to report a side effect
Free text change information supplied by the pharmaceutical company
Change to product name: update document title to align with SPC name
Section 4.8: Update to include new HPRA contact information
Section 4.8: Update to include new HPRA contact information
Updated on 14 October 2008
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Section 4.5 - Updated Interactions to include NSAIDS
Section 4.8 - Updated Undesirable effects to include allergic skin reactions, severe general rections, rare cases of emotional disorders including aggression in children.
Updated on 14 October 2008
Reasons for updating
- Change to section 4.5 - Interaction with other medicinal products and other forms of interaction
- Change to section 4.8 - Undesirable effects
Free text change information supplied by the pharmaceutical company
Section 4.5 - Updated Interactions to include NSAIDS
Section 4.8 - Updated Undesirable effects to include allergic skin reactions, severe general rections, rare cases of emotional disorders including aggression in children.
Updated on 16 October 2007
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
Change to section 9 (Date of Renewal of Authorisation): Changed to Date of first authorisation: 17th February 1977. Date of last renewal: 17th February 2007
Updated on 16 October 2007
Reasons for updating
- Change to section 9 - Date of renewal of authorisation
Free text change information supplied by the pharmaceutical company
Change to section 9 (Date of Renewal of Authorisation): Changed to Date of first authorisation: 17th February 1977. Date of last renewal: 17th February 2007
Updated on 27 August 2007
Reasons for updating
- Correction of spelling/typing errors
Legal category:Product subject to restricted prescription (C)
Free text change information supplied by the pharmaceutical company
eryeryeyghkghkghk
eryeryeryefjfhkjfgjh
Updated on 27 August 2007
Reasons for updating
- Correction of spelling/typing errors
Free text change information supplied by the pharmaceutical company
eryeryeyghkghkghk
eryeryeryefjfhkjfgjh
Updated on 27 June 2005
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Legal category:Product subject to restricted prescription (C)
Updated on 27 June 2005
Reasons for updating
- Change to section 7 - Marketing authorisation holder
- Change to section 10 - Date of revision of the text
Updated on 26 June 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to restricted prescription (C)
Updated on 26 June 2003
Reasons for updating
- New SPC for medicines.ie
Updated on 26 May 2003
Reasons for updating
- New SPC for medicines.ie
Legal category:Product subject to restricted prescription (C)
Updated on 26 May 2003
Reasons for updating
- New SPC for medicines.ie
Ferring Ireland Limited
Address:
United Drug House, Magna Drive, Magna Business Park, Citywest Road, Dublin 24, IrelandMedical Information E-mail:
Ferring@MedInformation.co.ukTelephone:
+44 (0) 800 111 4126Medical Information Direct Line:
+44 (0) 800 111 4126